Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant treatment of in-transit melanoma: Narrowing the knowledge gap left by clinical trials.
de Meza MM, Blokx WAM, Bonenkamp HJ, Blank CU, Aarts MJB, van den Berkmortel FWPJ, Boers-Sonderen MJ, de Groot JWB, Haanen JB, Hospers GAP, Kapiteijn EW, van Not OJ, Piersma D, van Rijn RS, Stevense-Den Boer MA, van der Veldt AAM, Vreugdenhil G, van den Eertwegh AJM, Suijkerbuijk KPM, Wouters MWJM. de Meza MM, et al. Among authors: blank cu. Int J Cancer. 2023 Jul 15;153(2):389-398. doi: 10.1002/ijc.34485. Epub 2023 Mar 8. Int J Cancer. 2023. PMID: 36843260
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Egeler MD, van de Poll-Franse LV, Tissier R, Rogiers A, Boers-Sonderen MJ, van den Eertwegh AJ, Hospers GA, de Groot JWB, Aarts MJB, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt AA, Suijkerbuijk KPM, Neyns B, Janssen KJ, Blank CU, Retèl VP, Boekhout AH. Egeler MD, et al. Among authors: blank cu. Qual Life Res. 2023 Sep;32(9):2517-2525. doi: 10.1007/s11136-023-03427-9. Epub 2023 Apr 20. Qual Life Res. 2023. PMID: 37079262
Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.
Borgers JSW, Burgers FH, Schina A, Van Not OJ, van den Eertwegh AJM, Blank CU, Aarts MJB, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Piersma D, van Rijn RS, Boer AMS, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Wouters MWJM, Suijkerbuijk KPM, van Thienen JV, Haanen JBAG. Borgers JSW, et al. Among authors: blank cu. Pigment Cell Melanoma Res. 2024 Jan;37(1):15-20. doi: 10.1111/pcmr.13117. Epub 2023 Aug 8. Pigment Cell Melanoma Res. 2024. PMID: 37554041
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Schmitt C, Hoefsmit EP, Fangmeier T, Kramer N, Kabakci C, Vera González J, Versluis JM, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies AM, Scolyer RA, Long GV, French LE, Blank CU, Heinzerling LM. Schmitt C, et al. Among authors: blank cu. Cancer Immunol Immunother. 2023 Nov;72(11):3475-3489. doi: 10.1007/s00262-023-03498-0. Epub 2023 Aug 22. Cancer Immunol Immunother. 2023. PMID: 37606856 Free PMC article.
Integrated noninvasive diagnostics for prediction of survival in immunotherapy.
Yeghaian M, Bodalal Z, Tareco Bucho TM, Kurilova I, Blank CU, Smit EF, van der Heijden MS, Nguyen-Kim TDL, van den Broek D, Beets-Tan RGH, Trebeschi S. Yeghaian M, et al. Among authors: blank cu. Immunooncol Technol. 2024 Jul 9;24:100723. doi: 10.1016/j.iotech.2024.100723. eCollection 2024 Dec. Immunooncol Technol. 2024. PMID: 39185322 Free PMC article.
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. Özkan A, et al. Among authors: blank cu. Eur J Cancer. 2024 Dec 26;216:115194. doi: 10.1016/j.ejca.2024.115194. Online ahead of print. Eur J Cancer. 2024. PMID: 39732138 No abstract available.
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Klop WMC, Torres Acosta A, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. Reijers ILM, et al. Among authors: blank cu. Eur J Cancer. 2025 Jan;214:115141. doi: 10.1016/j.ejca.2024.115141. Epub 2024 Nov 19. Eur J Cancer. 2025. PMID: 39602990 Clinical Trial.
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.
Vos JL, Traets JJ, Qiao X, Seignette IM, Peters D, Wouters MW, Hooijberg E, Broeks A, van der Wal JE, Karakullukcu MB, Klop WMC, Navran A, van Beurden M, Brouwer OR, Morris LG, van Poelgeest MI, Kapiteijn E, Haanen JB, Blank CU, Zuur CL. Vos JL, et al. Among authors: blank cu. JCI Insight. 2024 Nov 8;9(21):e179982. doi: 10.1172/jci.insight.179982. JCI Insight. 2024. PMID: 39513365 Free PMC article.
226 results